First patients to test new 'Double-Target' cancer drug

NCT ID NCT06952010

Recruiting now Disease control Sponsor: Exelixis Source: ClinicalTrials.gov ↗

Summary

This is the first study in people to test a new drug called XB628 for advanced solid tumors that have returned or spread. The main goal is to find a safe and effective dose by giving the drug to about 75 participants. XB628 is designed to help the body's own immune cells find and attack cancer cells in a new way.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Exelixis Clinical Site #1
RECRUITING

Hickory, North Carolina, 28602, United States
Exelixis Clinical Site #10
RECRUITING

Boston, Massachusetts, 02114, United States
Exelixis Clinical Site #2
RECRUITING

San Antonio, Texas, 78229, United States
Exelixis Clinical Site #3
RECRUITING

Nashville, Tennessee, 37203, United States
Exelixis Clinical Site #8
RECRUITING

Tampa, Florida, 33612, United States
Exelixis Clinical Site #9
RECRUITING

Houston, Texas, 77030, United States
Exelixis Site #4
RECRUITING

New Haven, Connecticut, 06520, United States
Exelixis Site #5
RECRUITING

San Francisco, California, 94158, United States
Exelixis Site #6
RECRUITING

St Louis, Missouri, 63108, United States
Exelixis Site #7
RECRUITING

New York, New York, 10029, United States

Conditions

Explore the condition pages connected to this study.

ADVANCED SOLID TUMOR IMMUNE SENSITIVE TUMOR METASTATIC SOLID TUMOR SOLID TUMOR